Alzheimer's has two devastating problems: we can't see it coming clearly enough, and we can't stop it once it starts.

We've built a solution that tackles both at once using two companion biologics that work as a unified system. Our published preclinical results are compelling — including demonstrated reversal of neurological damage. We are now preparing for clinical trials.

The first is a diagnostic biologic — an MRI contrast agent that makes damaged brain receptors visible on a scan, showing precisely where memory circuitry is breaking down and how severely.

The second is a treatment biologic — that delivers a therapeutic protein directly to those same damaged receptors. Unlike lecanemab and donanemab, which only slow the progression of Alzheimer's, our published preclinical results show actual reversal of neurological damage — something no approved treatment has achieved.

What makes this uniquely powerful is that the diagnosis drives the treatment. The MRI scan tells us exactly where to target, how much to give, and whether it's working — in real time. No guesswork.

Our AI-powered software platform ties it all together — tracking early Alzheimer's warning signs, calculating a personalized risk score, and delivering a fully documented Alzheimer's treatment strategy for clinicians.

The Alzheimer's diagnostic and the treatment, powered by AI. All Together. For the first time.

We are in IND-enabling studies targeting a Phase 1 first-in-human trials. Our regulatory strategy leverages the diagnostic biologic as the entry point, with the treatment biologic following under a companion diagnostic framework.